================================================================================ UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ---------------------------------- FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 10, 2004 TLC VISION CORPORATION (Exact name of registrant as specified in its charter) NEW BRUNSWICK 0-29302 980151150 (State or other (Commission File (I.R.S. Employer jurisdiction of Number) Identification Number) organization) 5280 SOLAR DRIVE, SUITE 300 L4W 5M8 MISSISSAUGA, ONTARIO (Zip Code) (Address of principal executive offices) Registrant's telephone number, including area code: (905) 602-2020 ================================================================================ ITEM 5. OTHER EVENTS On May 10, 2004, the Company issued a press release pertaining to an update with respect to its patented Rheopheresis(R) blood filtration process business ("RHEO"). A copy of that press release is attached hereto as an exhibit. ITEM 7. LIST OF EXHIBITS FILED (c) Exhibits 99.1 RHEO Update Press Release, dated May 10, 2004 * * * 2 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: May 11, 2004 TLC VISION CORPORATION By: /s/ Robert W. May ------------------------------------- Robert W. May General Counsel and Secretary 3 EXHIBIT INDEX <Table> <Caption> Exhibit No. Description - ----------- ----------- 99.1 RHEO Update Press Release, dated May 10, 2004 </Table> 4